As shown in Figure 3E, there is a significant decrease in γ-H2AX and PML nuclear body formation in response to mitochondria complex inhibitors, demonstrating that ROS generated by mitochondria is a necessary component of CIS development. The gene discussed is PML; the disease is in situ carcinoma.